29.11.2021 14:35:56
|
Vaccine Makers Investigate New Covid Variant, To Adapt Shots If Needed
(RTTNews) - Major covid vaccine makers said they are investigating Omicron, the new, heavily mutated coronavirus variant that was first detected in South Africa, and working to adapt their vaccines, if needed.
The World Health Organization, which named the new variant omicron, said the new strain is a "variant of concern" that could pose a higher risk of reinfection compared to the previous mutations.
Pfizer and BioNTech said they expect more data on the new variant, first labeled B.1.1.529, within two weeks, with which the companies could determine whether their vaccines need to be reworked on. The companies are expected to be able to redesign their shot tailored to the emerging variant within six weeks and ship initial batches within 100 days.
Moderna Inc. said it is working to advance a booster candidate tailored to the new variant. The company is also testing a higher dose of its existing booster and studying other booster candidates designed to protect against multiple variants.
Johnson and Johnson is also closely monitoring emerging strains of COVID-19 and is testing the effectiveness of its shot against the new variant emerged in South Africa.
AstraZeneca said it is investigating the variant, and is already conducting research in locations where the variant has been identified.
For fear of the new variant, which has about 50 mutations, the European Union and several other countries across the globe, including the U.S. And U.K, have suspended flights from South Africa and nearby countries.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
04.12.24 |
NASDAQ 100 aktuell: NASDAQ 100 beginnt Mittwochssitzung im Plus (finanzen.at) | |
03.12.24 |
NASDAQ 100 aktuell: NASDAQ 100 liegt letztendlich im Plus (finanzen.at) | |
03.12.24 |
Starker Wochentag in New York: NASDAQ 100 nachmittags mit Kursplus (finanzen.at) | |
03.12.24 |
NASDAQ 100 aktuell: NASDAQ 100 am Mittag in Rot (finanzen.at) | |
03.12.24 |
NASDAQ 100 aktuell: NASDAQ 100 beginnt die Dienstagssitzung in der Verlustzone (finanzen.at) | |
12.11.24 |
AstraZeneca-Aktie verliert: AstraZeneca steigert Umsatz im 3. Quartal und hebt Ausblick für 2024 an (Dow Jones) | |
11.11.24 |
Ausblick: AstraZeneca gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
07.11.24 |
AstraZeneca-Aktie tiefer: AstraZenecas China-Chef festgenommen - Behörden ermitteln (Dow Jones) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 63,00 | -0,79% | |
BioNTech (ADRs) | 111,40 | -0,71% | |
Johnson & Johnson | 139,46 | 0,46% | |
Moderna Inc | 38,48 | -1,13% | |
Pfizer Inc. | 25,23 | 0,62% |